| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1475 | Cl-nio Dihydrochloride | Novel inhibitor of the human enzyme dimethylarginine dimethylaminohydrolase-1 (DDAH-1) |
|
| DCC1476 | Clobetasol | Corticosteroid Hormone Receptor Agonist |
|
| DCC1477 | Clofibride | Hypolipaemic agent, reducing hypertriglyceridemia and hypercholesterolemia |
|
| DCC1478 | Cloquintocet | Herbicide safener that is added to various herbicide formulations to reduce crop damage |
|
| DCC1479 | Clorazepate Dipotassium | Long-acting benzodiazepine, producing the active metabolite desmethyl-diazepam, which is a partial agonist of the GABAA receptor |
|
| DCC1480 | Clotiazepam | Full agonist of GABAA receptors, acting as anxiolytic, sedative, hypnotic, amnesic, anticonvulsant and muscle relaxant agent |
|
| DCC1481 | Clr1404 | Precursor for tumor selective PET imaging (124I-CLR1404) or therapeutic radiation (131I-CLR1404) |
|
| DCC1482 | Cls405 | Novel chromophore-linked metallo-β-lactamase (MBL) substrate as potential inhibitor against a panel of clinically relevant MBLs |
|
| DCC1483 | cm-10-18 | Novel inhibitor of |
|
| DCC1484 | Cm-118 | Novel potent and selective dual inhibitor of c-Met and ALK, potently abrogating hepatocyte growth factor (HGF)-induced c-Met phosphorylation and cell migration, phosphorylation of ALK, EML4-ALK, and ALK resistance mutants in transfected cells |
|
| DCC1485 | Cm-157 | Novel selective agonist of cannabinoid CB2 receptors |
|
| DCC1486 | Cm-352 | Novel Matrix Metalloproteinase Inhibitor As a Potent Antihemorrhagic Agent |
|
| DCC1487 | Cm-407 | First-in-class dual PDE5 and HDAC6-selective inhibitor |
|
| DCC1488 | Cm-444 | Novel Epigenetic Inhibitor Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma |
|
| DCC1489 | cm-9-78 | Novel inhibitor of |
|
| DCC1490 | Cmap-7 | Novel Hedgehog pathway inhibitor, revealing the receptor GPR39 |
|
| DCC1491 | Cmb4563 | Novel Potent and Specific Target Of Rapamycin Complex 2 (TORC2) Inhibitor |
|
| DCC1492 | Cmcofx1 | Novel ultrapotent and selective inhibitor of of human β-Factor XIIa |
|
| DCC1493 | Cmd178 Tfa Salt | Novel peptide STAT5 inhibitor, blocking IL-2/sIL-2Rα signaling and inhibiting T reg cell development |
|
| DCC1494 | Cm-ff-h | Novel SARS-CoV Mpro inhibitor which has its P1-phenylalanine residue bound to the relatively hydrophilic S1 pocket of the enzyme and yet exhibits a high inhibitory activity against SARS-CoV Mpro, with Ki = 2.24 ± 0.58 μM |
|
| DCC1495 | Cmi-392 | Potent dual 5-lipoxygenase (5-LOX) inhibitor and platelet-activating factor (PAF) receptor antagonist |
|
| DCC1496 | cmpd 339509 | Inhibitor of DprE1, an epimerase required for cell wall biosynthesis |
|
| DCC1497 | Cmpd-15pa | Novel allosteric modulator of the β2 adrenergic receptor (β2AR), binding to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8 |
|
| DCC1498 | Cmpi Hydrochloride | Selective and potent potentiator of nAChRs containing an α4 |
|
| DCC1499 | Cmx020 | Novel TRPV1 modulator, also modulating both CB1 and CB2 receptors |
|
| DCC1500 | Cmx521 | Novel Inhibitor for RNA-Dependent RNA Polymerase of Norovirus |
|
| DCC1501 | Cn14_17 | Novel Potent Inhibitor of the HIV-1 Nucleocapsid Protein |
|
| DCC1502 | Cn-716 | Novel Zika virus (ZIKV) NS2B-NS3pro protease inhibitor |
|
| DCC1503 | cn-chalc4 | Novel blocker of binding of CXCL12 to CXCR4 |
|
| DCC1504 | Cng-10300 | Novel partial blocker of GluK1, with GluK2 being unaffected |
|
